Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.51 |
| ▸ | PLK2 | Q9NYY3 | 15/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 13/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10319396 | 1.00 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL382821 | 1.00 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL30523195 | 1.00 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL1288242 | 0.98 | PLK1 (0.49) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL1288243 | 0.98 | PLK1 (0.49) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL5936768 | 0.95 | PLK1 (0.46) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL31098106 | 0.92 | PLK1 (0.44) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL5936900 | 0.90 | PLK1 (0.43) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL14952207 | 0.88 | PLK1 (0.43) | PLK1PLK2PLK3BRD4KDM4E | |
| SCHEMBL23849199 | 0.87 | PIP4K2A (0.41) | PLK1PLK2PLK3BRD4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316054-A1 | NOVEL PLK1 PROTEIN DEGRADATION-INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| CN-118047779-A | Dihydropteridinone derivatives containing benzobisheteroaryl and use thereof | 沈阳药科大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-116396295-A | Synthesis method of PLK1 degradation agent based on PROTAC | 合肥工业大学 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023277583-A1 | NOVEL PLX1 PROTEIN DEGRADATION-INDUCING COMPOUND | (주) 업테라 | 2023-01-05 | — | — | WO | disclosed |
| CN-106977584-B | Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof | JILIN UNIVERSITY (CN) | 2019-12-06 | — | — | CN | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2436685-B1 | Intermediate products for producing annulated piperazine-2-on derivatives | BOEHRINGER INGELHEIM INT (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-2436685-B1 | Intermediate products for producing annulated piperazine-2-on derivatives | BOEHRINGER INGELHEIM INT (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| EP-1819706-A1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-7241889-B2 | 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241889-B2 | 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-20060122393-A1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058876-A1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | PLK1 2/4885PLK2 18/4885PLK3 76/4885 |
| US-20240316054-A1 | NOVEL PLK1 PROTEIN DEGRADATION-INDUCING COMPOUND | PLK1, BRD4, BUB1B | PLK1 1/4885PLK2 43/4885PLK3 97/4885 |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | PLK1 637/4885PLK2 342/4885PLK3 1005/4885 |
| US-20060122393-A1 | Process for the manufacture of fused piperazin-2-one derivatives | DPYD, CYP1B1, DHFR | PLK1 332/4885PLK2 359/4885PLK3 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.